Answers are grounded in this paper and cite their sources.
Systemic therapy of melanoma has made tremendous progress recently for advanced stage patients in terms of excellent, temporary responses through targeting underlying biology of BRAF V600E mutation and affected pathways. A significant subset of patients with advanced disease also has durable responses from immunomodulation through immune checkpoint blockade of CTLA-4 and the PDL-1/PD-1 axis. Clinical trials of these agents included patients as young as 18 years but generally excluded younger adolescents. Ongoing trials in 12–17 year olds have not been accruing as robustly, and as a result available options for these patients are often lagging years behind their adult counterparts. We herein summarize the epidemiology, diagnosis, and multidisciplinary management of adolescents and young adults with melanoma. We offer recommendations to improve the care for adolescent patients with melanoma age-specific evaluations and by including them in up-front melanoma trials.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: